Arcutis Reports Strong Q4 & FY2025 Results, Achieves Positive Cash Flow, and Raises 2026 Revenue Guidance

summarizeSummary

Arcutis Biotherapeutics announced strong Q4 and full-year 2025 financial results, including significant revenue growth for ZORYVE, the achievement of positive operating cash flow, and an increase in its 2026 full-year net product sales guidance.

check_boxKey Events

• Strong ZORYVE Revenue Growth

  Q4 2025 net product revenue for ZORYVE reached $127.5 million, an 84% increase year-over-year, contributing to a full-year 2025 revenue of $372.1 million, up 123% from 2024.

• Achieved Positive Operating Cash Flow

  The company reported $26.2 million in positive operating cash flow for Q4 2025 and expects to maintain positive operating cash flow quarterly going forward, marking a significant financial milestone.

• Raised 2026 Full-Year Revenue Guidance

  Arcutis increased its 2026 net product revenue guidance to between $480 million and $495 million, up from the previous range of $455 million to $470 million, reflecting a strong commercial outlook.

• Positive Phase 2 Trial Data for ZORYVE in Infants

  Positive topline results were reported for the INTEGUMENT-INFANT Phase 2 study of ZORYVE cream 0.05% in infants with atopic dermatitis, with a Supplemental New Drug Application (sNDA) submission planned for Q2 2026.

auto_awesomeAnalysis

Arcutis Biotherapeutics reported robust financial results for the fourth quarter and full-year 2025, driven by exceptional demand for its lead product, ZORYVE. A pivotal highlight is the achievement of positive operating cash flow in Q4 2025, with management projecting this positive trend to continue, signaling a significant improvement in financial health and sustainability. The upward revision of 2026 full-year net product sales guidance underscores strong commercial momentum and increased confidence in ZORYVE's market penetration and expansion into new age groups and indications. Additionally, positive clinical data for ZORYVE in infants and ongoing regulatory progress for other indications further strengthen the product's long-term growth potential and pipeline, complemented by a new patent extending exclusivity for the foam formulation.